Jin Daoqun, Wu Yongbo, Zhao Lin, Guo Jie, Zhang Kai, Chen Zhiqiang
Department of Cardiology, Central Hospital of Huangshi, Huangshi, P.R. China.
Exp Ther Med. 2012 Dec;4(6):1124-1126. doi: 10.3892/etm.2012.732. Epub 2012 Oct 1.
High mobility group box 1 protein (HMGB1) has been identified as a novel pro-inflammatory cytokine in coronary artery disease. This study investigated the effect of atorvastatin on serum HMGB1 levels in patients with hyperlipidemia. In 72 patients with hyperlipidemia, serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) were compared with the levels in 32 control patients. In hyperlipidemic patients, serum HMGB1 levels were also determined by ELISA before and after a 3-month treatment of atorvastatin (20 mg/day). TC and LDL-C levels in the hyperlipidemic group (6.37±0.94 and 4.99±0.75 mmol/l, respectively) were significantly higher compared to those in the control group (4.34±0.89 and 2.57±0.82 mmol/l, respectively) (both P<0.05). Hs-CRP and HMGB1 levels in the hyperlipidemic group (3.91±1.06 mg/l and 5.42±1.56 ng/ml, respectively) were also significantly higher compared to those in the control group (1.53±0.45 mg/l and 2.11±0.95 ng/ml, respectively) (both P<0.05). After treatment with atorvasatin for three months, TC and LDL-C levels in the hyperlipidemic group were significantly decreased compared to those prior to treatment (TC, 4.67±0.89 vs. 6.37±0.94 mmol/l and LDL-C, 2.75±0.92 vs. 4.99±0.75 mmol/l, respectively) (both P<0.05). HMGB1 and hs-CRP levels in the hyperlipidemic group (3.07±1.24 ng/ml and 1.87±0.79 mg/l, respectively) were also significantly decreased compared to levels prior to treatment (5.42±1.56 ng/ml and 3.91±1.06 mg/l, respectively) (both P<0.05). Serum HMGB1 levels are increased in patients with hyperlipidemia which could be reduced by atorvastatin.
高迁移率族蛋白B1（HMGB1）已被确认为冠状动脉疾病中的一种新型促炎细胞因子。本研究调查了阿托伐他汀对高脂血症患者血清HMGB1水平的影响。将72例高脂血症患者的血清总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）和高敏C反应蛋白（hs-CRP）水平与32例对照患者的水平进行比较。在高脂血症患者中，还通过酶联免疫吸附测定法（ELISA）在阿托伐他汀（20毫克/天）治疗3个月前后测定血清HMGB1水平。高脂血症组的TC和LDL-C水平（分别为6.37±0.94和4.99±0.75毫摩尔/升）显著高于对照组（分别为4.34±0.89和2.57±0.82毫摩尔/升）（均P<0.05）。高脂血症组的hs-CRP和HMGB1水平（分别为3.91±1.06毫克/升和5.42±1.56纳克/毫升）也显著高于对照组（分别为1.53±0.45毫克/升和2.11±0.95纳克/毫升）（均P<0.05）。阿托伐他汀治疗三个月后，高脂血症组的TC和LDL-C水平与治疗前相比显著降低（TC，4.67±0.89对6.37±0.94毫摩尔/升；LDL-C，2.75±0.92对4.99±0.75毫摩尔/升）（均P<0.05）。高脂血症组的HMGB1和hs-CRP水平（分别为3.07±1.24纳克/毫升和1.87±0.79毫克/升）也与治疗前水平（分别为5.42±1.56纳克/毫升和3.91±1.06毫克/升）相比显著降低（均P<0.05）。高脂血症患者的血清HMGB1水平升高，但可通过阿托伐他汀降低。
